about
The risk factors and prevention of cardiovascular disease: the importance of electrocardiogram in the diagnosis and treatment of acute coronary syndromeDevelopment and validation of a high throughput whole blood thrombolysis plate assay.Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy.Data supporting the structural and functional characterization of Thrombin-Activatable Fibrinolysis Inhibitor in breast cancerClinical utility of the ratio between circulating fibrinogen and fibrin (ogen) degradation products for evaluating coronary artery disease in type 2 diabetic patients.Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis.Early effects of paroxysmal atrial fibrillation on plasma markers of fibrinolysisHypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.Clot-entrapped blood cells in synergy with human mesenchymal stem cells create a pro-angiogenic healing response.Widely Used Types and Clinical Applications of D-Dimer Assay.The evolution of recombinant thrombolytics: Current status and future directionsEndothelial cells: source, barrier, and target of defensive mediators.Nuclear imaging of thrombosis in small animal.New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.Global assays of fibrinolysis.Blood-Brain Barrier Disruption, Vascular Impairment, and Ischemia/Reperfusion Damage in Diabetic Stroke.Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single-Chain Antibody Specific for Activated GPIIb/IIIa.A Case of Unexplained Cerebral Sinus Thrombosis in a 22-Year-Old Obese Caucasian WomanPeptide Mimetic Drugs for Modulating Thrombosis and Hemostasis.Coagulation Testing in the Core Laboratory.Peri-operative blood-loss after total hip arthroplasty can be significantly reduced with topical application of epsilon-aminocaproic acid.NOTCH1 is a mechanosensor in adult arteries.Fibrin-Enhanced Canonical Wnt Signaling Directs Plasminogen Expression in Cementoblasts.Pediatric Thrombolysis: A Practical Approach.Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.Analysis of factor XIa, factor IXa and tissue factor activity in burn patients.Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia.Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.Antifibrinolytic Therapy and Perioperative Considerations.Endothelial Cells.Ixonnexin from Tick Saliva Promotes Fibrinolysis by Interacting with Plasminogen and Tissue-Type Plasminogen Activator, and Prevents Arterial Thrombosis.Dry Socket Etiology, Diagnosis, and Clinical Treatment Techniques.Comparative proteomic analysis revealed complex responses to classical/novel duck reovirus infections in Cairna moschata.Plasminogen-binding proteins as an evasion mechanism of the host's innate immunity in infectious diseases
P2860
Q26740361-4A7A6C9E-AE47-4958-84E1-5487877D7FE0Q33725847-A7A51306-349C-43E2-B0EE-60C89B8C636BQ33742612-5044004B-AA94-4590-8827-F01530F97ED3Q35887881-57F119BD-648F-4965-A4AD-4660B02DEE4DQ36804738-91F5C454-4B45-499B-804C-2F7D9BB5C103Q37401506-E47FB3ED-9228-4AA7-ACA3-713157667E83Q37409534-E2DBE8FD-1E09-4D32-BB46-E7C425176A94Q37692590-76EDF82C-9B3F-44BB-9C9E-47CE97F51244Q38624044-409CD7CB-7DB6-47CC-84D8-01F555C92778Q38789567-87910568-3738-4474-B043-377B9E461119Q38803641-51C139EB-79E1-4434-B87D-73DB3F03D2B2Q38991026-BBDBD883-5275-4896-B52F-AB3868DC333EQ39023336-6D2688B3-C2DF-4666-B182-93F1226A4276Q39213540-5AF184EF-7621-4FAD-AD45-4594F8977CB4Q39301841-C71097A5-8A8E-46A7-9F72-A9C6562F0ABAQ39345035-5E1DA248-3AFE-4982-BB24-9041F2908E57Q41102431-C41A3E64-7605-44E2-BEE9-FA7B06D84BB9Q41821585-E9254080-F208-4199-B908-A8FE93D06FA9Q44874794-E4ACDCA2-5157-4134-A1FB-4882B123BAD0Q45874296-4E4F4709-E3C3-46D1-B908-6A5FD3A014C3Q45968801-903190A1-FA87-449C-A371-79CCEF10BDEDQ46268039-56594227-D039-41B6-AC43-F8B479523320Q46273924-F16AAE96-543C-4167-B52F-29C837869705Q47137542-DD245410-E241-4C1E-A451-8223B527668DQ47324534-123379D6-3CC3-46C3-A928-6D807424F5D1Q47651258-BF82E38B-4982-4B83-BC62-3FF5C9935320Q47927617-9B6CB1EA-C3E5-47DC-9233-0469E3EBD735Q50067342-417DFCF9-7252-4C46-857E-94841F26126CQ50099821-6E0B1A94-A8B4-4406-ADC5-4773C4661975Q50864381-B5EC95AB-0C6A-42EF-AA92-D7A395B34C9EQ52349793-EBD45D64-975E-43B0-AED3-3BDCEC80C48BQ55336413-45F55106-F88E-424C-A588-9C9AC57F716FQ55546789-35E2C486-8C1F-48DB-8A50-BB8445BF448FQ57044366-EAD68CD3-37FB-4DE1-86C2-72432C46B857
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Fibrinolysis and the control of blood coagulation.
@ast
Fibrinolysis and the control of blood coagulation.
@en
type
label
Fibrinolysis and the control of blood coagulation.
@ast
Fibrinolysis and the control of blood coagulation.
@en
prefLabel
Fibrinolysis and the control of blood coagulation.
@ast
Fibrinolysis and the control of blood coagulation.
@en
P2860
P1433
P1476
Fibrinolysis and the control of blood coagulation.
@en
P2093
John C Chapin
Katherine A Hajjar
P2860
P356
10.1016/J.BLRE.2014.09.003
P577
2014-09-16T00:00:00Z